Head and neck squamous cell carcinoma affects more than 500,000 people worldwide each year. Despite optimal treatment with surgery, irradiation, and chemotherapy, disease recurrence and progression remains a common and challenging oncological problem. Recently, interest has developed in identifying novel molecular markers that allow identification of those patients at increased risk for locoregional recurrence and death. This article reviews several such molecular markers studied in head and neck cancer, including p53, angiogenesis-related markers, cyclin D1, and epidermal growth factor receptor. The biological function of these markers and the potential clinical implications are discussed. The purpose of this review is to update the otolaryngologist on a rapidly emerging segment of applied translational research in our field.
ParkinDMLaaraEMuirCS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer1988; 41: 184–97.
2.
SwangoPA. Cancers of the oral cavity and pharynx in the United States: An epidemiologic overview. J Public Health Dent1996; 56: 309–18.
3.
HafftyBG. Concurrent chemoradiation in the treatment of head and neck cancer. Hematol Oncol Clin North Am1999; 13: 719–42.
4.
BrizelDMAlbersMEFisherSR. Hyperfractionated irradiation with or without concurrent chemotherapy of locally advanced head and neck cancer. N Engl J Med1998; 338: 1798–803.
5.
OvergaardJ. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res1994; 6: 509–18.
6.
HafftyBSonYHPapacR. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol1997; 15: 268–76.
7.
RockwellS. Oxygen delivery: Implications for the biology and therapy of solid tumors. Oncol Res1997; 9: 383–90.
8.
HoriotJCBontempsPvan den BogaertW. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol1997; 44: 111–21.
9.
MunroAJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer1995; 71: 83–91.
10.
MauceriHJHannNNBeckettMA. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature1998; 394: 287–91.
11.
VokesEEAthanasiadiaI. Chemotherapy for squamous cell carcinoma of the head and neck: The future is now. Ann Oncol1996; 7: 15–29.
12.
BrownJMSiimBG. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol1996; 6: 22–36.
13.
ForastiereAAUrbaSG. Single-agent paclitaxel plus ifos-famide in the treatment of head and neck cancer. Semin Oncol1995; 22: 24–7.
14.
StellPM. Ploidy in head and neck cancer: A review and meta-analysis. Clin Otolaryngol1991; 16: 510–6.
15.
LaneDP. p53, Guardian of the genome. Nature1992; 358: 15–6.
16.
LaneDP. The regulation of p53 function: Steiner Award lecture. Int J Cancer1994; 57: 623–7.
17.
HunterT. Braking the cycle. Cell1993; 75: 839–41.
18.
Yonish-RouachEResnitzkyDLotemJSachsLKimchiAOrenM. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature1991; 352: 345–7.
19.
ClarkeARPurdieCAHarrisonDJ. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature1993; 362: 849–52.
20.
LoweSWSchmittEMSmithSWOsborneBAJacksT. p53 Is required for radiation-induced apoptosis in mouse thymocytes. Nature1993; 362: 847–9.
21.
LoweSWRuleyHEJacksTHousmanDE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell1993; 74: 957–67.
22.
BlankKRRudoltzMSKaoGDMuschellRJMcKennaWG. The molecular regulation of apoptosis and implications for radiation oncology. Int J Radiat Biol1997; 71: 455–66.
23.
ChangEHJangYJHaoZ. Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Arch Otolaryngol Head Neck Surg1997; 123: 507–12.
24.
PirolloKFHaoZRaitA. p53 Mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene1997; 14: 1735–46.
25.
GraeberTGOsmanianCJacksT. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature1996; 379: 88–91.
26.
JenkinsJRRudgeKChumakovPCurrieGA. The cellular oncogene p53 can be activated by mutagenesis. Nature1985; 317: 816–8.
27.
IggoRGatterKBartekJLaneDHarrisAL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet1990; 335: 675–9.
28.
KochWMBrennanJAZahurakM. p53 Mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst1996; 88: 1580–6.
29.
ShinDMLeeJSLippmanSM. p53 Expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst1996; 88: 519–29.
30.
CamineroMJNunezFSuarezCAblanedoPRieraJRDominguezF. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. Arch Otolaryngol Head Neck Surg1996; 122: 769–72.
31.
Raybaud-DiogeneHFortinAMorencyRRoyJMonteilRATetuB. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J Clin Oncol1997; 15: 1030–8.
32.
NarayanaAVaughanATKathuriaSFisherSGWalterSAReddySP. p53 Overexpression is associated with bulky tumor and poor local control in T1 glottic cancer [Abstract]. Int J Radiat Oncol Biol Phys1998; 42(suppl): 146.
33.
MichalidesRJvan VeelenNMKristelPM. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg1997; 123: 497–502.
34.
GluckmanJLPavelicZPWelkoborskyHJ. Prognostic indicators for squamous cell carcinoma of the oral cavity: A clinicopathologic correlation. Laryngoscope1997; 107: 1239–44.
35.
VeneroniSSilvestraniRCostaASalvatoriPFarandaAMolinariR. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncol1997; 33: 408–13.
36.
PaiHHRochonLClarkBBlackMShenoudaG. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys1998; 41: 37–42.
FolkmanJ. Tumor angiogenesis. Adv Cancer Res1985; 43: 175–203.
39.
KlagsbrunMD'AmorePA. Regulators of angiogenesis. Annu Rev Physiol1991; 53: 217–39.
40.
KlagsbrunMSokerS. VEGF/VPF: The angiogenesis factor found?Curr Biol1993; 3: 699–702.
41.
PlateKHBreierGWeichHARisauW. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature1992; 359: 845–8.
42.
ShweikiDItinASofferDKeshetE. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature1992; 359: 843–5.
43.
ShweikiDNeemanMItinAKeshetE. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci U S A1995; 92: 768–72.
44.
HlatkyLTsionouCHahnfeldtPColemanCN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res1994; 54: 6083–6.
45.
KrollJWaltenbergerJ. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem1997; 272: 32521–7.
46.
WeidnerNSempleJPWelchWRFolkmanJ. Tumor angiogenesis and metastasis — Correlation in invasive breast carcinoma. N Engl J Med1991; 324: 1–8.
47.
WilliamsJKCarlsonGWCohenCDerosePBHunterSJurkiewiczMJ. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg1994; 168: 373–80.
48.
AlcaldeREShintaniSYoshihamaYMatsumaraT. Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma. Anticancer Res1995; 15: 1417–22.
49.
ShpitzerTChaimoffMGalRSternYFeinmesserRSegalK. Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg1996; 122: 865–8.
50.
AlcaldeRETerakadoNOtsukiKMatsumaraT. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology1997; 54: 324–8.
51.
DrayTGHardinNJSoffermanRA. Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol1995; 104: 724–9.
52.
SalvenPHeikkilaPAnttonenAKajantiMJoensuuH. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance. Mod Pathol1997; 10: 1128–33.
53.
DenhartBCGuidiAJTognazziKDvorakHFBrownLF. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest1997; 77: 659–64.
54.
MaedaTMatsumuraSHiranumaH. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: Its association with tumour progression and p53 gene status. J Clin Pathol1998; 51: 771–5.
55.
EismaRJSpiroJDKreutzerDL. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg1997; 174: 513–7.
56.
MotokuraTBloomTKimHG. A novel cyclin encoded by a bc 11-linked candidate oncogene. Nature1991; 350: 512–5.
ZwijsenRMKlompmakerRWientjensEBKristelPMvan der BurgBMichalidesRJ. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol1996; 16: 2554–60.
59.
AlaviSNamazieACalcaterraTCWangTCSrivatsanES. Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Laryngoscope1999; 109: 874–9.
60.
PignataroLPruneriGCarboniN. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol1998; 16: 3069–77.
61.
MeredithSDLevinePABurnsJA. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg1995; 121: 790–4.
62.
BellacosaAAlmadoriGCavalloS. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: Prognostic significance and clinical implications. Clin Cancer Res1996; 2: 175–80.
63.
AkervallJAMichalidesRJMinetaH. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer1997; 79: 380–9.
64.
KyomotoRKumazawaHTodaY. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein overexpression in human head-and-neck squamous-cell carcinoma. Int J Cancer1997; 74: 576–81.
65.
NogueiraCPDolanRWGooeyJ. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope1998; 108: 345–50.
66.
MullerDMillonRVeltenM. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: Correlation with clinical outcome. Eur J Cancer1997; 33: 2203–10.
67.
FortinAGuerryMGuerryR. Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: No correlation with subclinical lymph node invasion and disease recurrence. Clin Cancer Res1997; 3: 1609–14.
68.
YooSCarterDTurnerB. Prognostic significance of cyclin D1 protein levels in early stage larynx cancer treated with primary radiation. Int J Cancer Radiat Oncol Invest2000; 90: 22–8.
MatthiasCBraniganKJahnkeV. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res1998; 4: 2411–8.
71.
GrandisJRTweardyDJ. Elevated levels of transforming growth factor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res1993; 53: 3579–84.
72.
GrandisJRMelhemMFBarnesELTweardyDJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer1996; 78: 1284–92.
GrandisJRChakrabortyAZengQMelhemMFTweardyDJ. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem1998; 69: 55–62.
75.
GrandisRubin JChakrabortyAMelhemMFZengQTweardyDJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene1997; 15: 409–16.
76.
HuangSMBockJMHarariPM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res1999; 59: 1935–40.
77.
KwokTTSutherlandRM. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. J Natl Cancer Inst1989; 81: 1020–4.
78.
KwokTTSutherlandRM. Differences in EGF related radiosensitization of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer1991; 64: 251–4.
79.
BonnerJAMaihleNJFolvenBRChristiansonTJSpainK. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys1994; 29: 243–7.
80.
DassonvilleOFormentaJFrancoualM. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol1993; 11: 1873–8.
81.
MauriziMAlmadoriGFerrandinaG. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer1996; 74: 1253–7.
82.
AlmadoriGCadoniGGalliJ. Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse. Int J Cancer1999; 84: 188–91.
83.
GrandisJRMelhemMGoodingW. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst1998; 90: 824–32.
84.
WenQHMiwaTYoshizakiTNagayamaIFurukawaMNishijimaH. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope1996; 106: 884–5.
85.
BrennanJASidranskyD. Molecular staging of head and neck squamous carcinoma. Cancer Metastasis Rev1996; 15: 3–10.
86.
ClaymanGLLiuTJOverholtSM. Gene therapy for head and neck cancer: Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg1996; 122: 489–93.
87.
RoccoJWLiDLiggettWH. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res1998; 4: 1697–704.
88.
MendelsohnJ. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res1997; 3: 2703–7.
89.
WheelerRHSpencerSBuchsbaumDRobertF. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Curr Opin Oncol1999; 11: 187–90.
